Received: 17 December 2019
Accepted: 22 June 2020
First Online: 14 July 2020
Ethics approval and consent to participate
: The research use of the data collected was approved by the Institutional Review Board (IRB) of the Dokuz Eylul University, Izmir, Turkey (305-SBDAEK).
: Patients gave consent to use their data for research purposes. The images used in the manuscript are entirely unidentifiable and there are no personal details on individuals reported within the manuscript.
: EAO was partially supported by the Lipodystrophy Fund at University of Michigan graciously contributed by the Sopha Family and the White Point Foundation of Turkey. EAO received grant support from and served as an advisor to Amylin Pharmaceuticals LLC, Bristol-Myers Squibb, AstraZeneca and Aegerion Pharmaceuticals in the past and is currently receiving grant support directly related to Lipodystrophy Treatment from Gemphire Therapeutics, Ionis Pharmaceuticals, and Akcea Therapeutics and serving as an advisor to Akcea Therapeutics, Regeneron Pharmaceuticals. EAO is also receiving grant support from GI Dynamics in an unrelated metabolic disease area. B.A. has attended Scientific Advisory Board Meetings organized by Aegerion Pharmaceuticals and Regeneron Pharmaceuticals, and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. Other authors have nothing to disclose.